Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Minority Interest
The portion of consolidated subsidiaries' equity owned by outside shareholders.
Quest Diagnostics IncorporatedNYSE: DGX
Minority Interest · Q3 FY2026 · quarter ended Sep 2026
Minority interest rises 238.1% from a year ago
Minority interest stood at $399M at the end of Q3 FY2026, up 238.1% from a year earlier and up 31.7% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Minority interest amounted to 2.3% of total assets at the end of Q3 FY2026, up 1.6 pp from a year earlier.
- Minority interest increased in 1 of the last 3 fiscal years.
What to watch
Whether minority interest keeps rising in the next quarterly balance sheet after a +238.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Minority Interest history
USD · from the balance sheet
- Latest · FY2025
- 116M USD
- Year-over-year change
- -1.7%
- 4-year CAGR
- -0.4%
| Period | Period end | Minority Interest | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116M | -1.7% |
| FY2024 | 2024-12-31 | 118M | +6.3% |
| FY2023 | 2023-12-31 | 111M | -2.6% |
| FY2022 | 2022-12-31 | 114M | -3.4% |
| FY2021 | 2021-12-31 | 118M | — |
Minority Interest vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's Sep 2026 minority interest of $399M is the highest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of +238.1% is the highest of 3, against a peer median of +10.9%.
- Minority interest amounts to 2.3% of total assets for DGX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $399M | +238.1% | +0.6% | 2.3% | |
| Sep 2026 | $315.58M | +23.6% | +18.8% | 7.4% | |
| Jun 2026 | $16.4M | -1.8% | -3.7% | 0.1% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Jul 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DGX) | $0 | +10.9% | +7.6% | 0.0% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 872M | 315M | 686M | 549M | 420M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.44B | 1.2B | 1.21B | 1.3B | 1.41B |
| Inventory | 208M | 192M | 190M | 188M | 189M |
| Other Current Assets | 187M | 196M | 286M | 351M | 361M |
| Total Current Assets | 2.74B | 1.9B | 2.37B | 2.39B | 2.38B |
| Property, Plant & Equipment (Net) | 2.3B | 2.35B | 2.42B | 2.76B | 2.86B |
| Goodwill | 7.1B | 7.22B | 7.73B | 8.86B | 8.95B |
| Intangible Assets | 1.17B | 1.09B | 1.17B | 1.76B | 1.64B |
| Long-term Investments | 141M | 132M | 135M | 123M | 136M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 163M | 144M | 198M | 255M | 270M |
| Total Non-current Assets | 10.87B | 10.94B | 11.65B | 13.76B | 13.85B |
| Total Assets | 13.61B | 12.84B | 14.02B | 16.15B | 16.23B |
| Account Payables | 357M | 324M | 378M | 287M | 1.6B |
| Short-term Debt | 269M | 247M | 585M | 937M | 678M |
| Tax Payables | 10M | 2M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 599M | 550M | 471M | 466M | 0 |
| Total Current Liabilities | 1.75B | 1.55B | 1.82B | 2.17B | 2.28B |
| Long-term Debt | 4.01B | 3.98B | 4.41B | 5.6B | 5.7B |
| Deferred Tax Liabilities | 290M | 295M | 270M | 250M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 502M | 517M | 606M | 688M | 420M |
| Total Non-current Liabilities | 5.3B | 5.28B | 5.79B | 7.09B | 6.66B |
| Total Liabilities | 7.05B | 6.83B | 7.6B | 9.26B | 8.94B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 7.65B | 8.29B | 8.83B | 9.36B | 9.99B |
| Accumulated OCI | (14M) | (21M) | (14M) | (88M) | (27M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 118M | 114M | 111M | 118M | 116M |
| Total Equity | 6.56B | 6.01B | 6.42B | 6.9B | 7.29B |
| Total Debt | 4.77B | 4.71B | 5.5B | 7.09B | 6.92B |
| Net Debt | 3.9B | 4.4B | 4.81B | 6.54B | 6.5B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.